» Articles » PMID: 36894927

Controlling Nutritional Status (CONUT) Score is a Prognostic Marker in III-IV NSCLC Patients Receiving First-line Chemotherapy

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2023 Mar 9
PMID 36894927
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To investigate the prognostic impact of the controlling nutritional status (CONUT) score in non-small-cell lung cancer (NSCLC) patients receiving first-line chemotherapy.

Methods: We retrospectively reviewed 278 consecutive patients undergoing chemotherapy for stage III-IV NSCLC between May 2012 and July 2020. CONUT score was calculated by incorporating serum albumin, total cholesterol, and total lymphocyte count. The patients were divided into two groups: CONUT ≥ 3 and CONUT < 3, according to receiver operating characteristic (ROC) analysis. The associations of CONUT with clinicopathological factors and survival were evaluated.

Results: A high CONUT score was significantly associated with older age(P = 0.003), worse ECOG-PS(P = 0.018), advanced clinical stage(P = 0.006), higher systematic inflammation index (SII) (P < 0.001)and lower prognostic nutritional index (PNI) (P < 0.001).The high CONUT group had a significantly shorter progression-free survival(PFS) and overall survival(OS) than the low CONUT group. In the univariate analysis, higher SII, higher CONUT, advanced clinical stage and lower PNI were associated with worse PFS (P < 0.05). Worse ECOG-PS, higher SII, higher CONUT, advanced clinical stage and lower PNI were associated with worse OS (P < 0.05). In multivariate analysis, CONUT(HR, 2.487; 95%CI 1.818 ~ 3.403; P < 0.001) was independently associated with PFS, while PNI(HR, 0.676; 95%CI 0.494 ~ 0.927; P = 0.015) and CONUT(HR, 2.186; 95%CI 1.591 ~ 3.002; P < 0.001)were independently associated with OS. In ROC analysis, CONUT had a higher area under the ROC curve (AUC) for the prediction of 24-month PFS and OS than the SII or PNI. When the time-dependent AUC curve was used to predict PFS and OS, CONUT tended to maintain its predictive accuracy for long-term prognosis at a significantly higher level for an extended period after chemotherapy when compared with the other markers tested. The CONUT score showed better accuracy of predicting OS (C-index: 0.711) and PFS(C-index: 0.753).

Conclusion: CONUT score is an independent prognostic indicator of poor outcomes for patients with stage III-IV NSCLC and is superior to the SII and PNI in terms of prognostic ability.

Citing Articles

Is nutritional status a new indicator to use in clinical practice for colorectal cancer patients?.

Berardi R, Chiariotti R, Mentrasti G World J Gastrointest Oncol. 2024; 16(12):4537-4542.

PMID: 39678789 PMC: 11577381. DOI: 10.4251/wjgo.v16.i12.4537.


Association of the Preoperative Controlling Nutritional Status (CONUT) Score with Clinicopathological Characteristics in Patients with Papillary Thyroid Carcinoma.

Kim D, Im M, Ryang S, Kim M, Jeon Y, Kim S Endocrinol Metab (Seoul). 2024; 39(6):856-863.

PMID: 39543965 PMC: 11695482. DOI: 10.3803/EnM.2024.2006.


Prognostic Significance of CONUT Score in Elderly NSCLC.

Tamura M, Sakai T, Furukawa N, Yamamoto M, Miyazaki R, Okada H Ann Thorac Cardiovasc Surg. 2024; 30(1).

PMID: 38569836 PMC: 11082491. DOI: 10.5761/atcs.oa.24-00009.


Prognostic and clinicopathological significance of the Controlling Nutritional Status (CONUT) score in patients with lymphoma: a meta-analysis.

Li L, Shou L BMJ Open. 2024; 14(3):e078320.

PMID: 38453197 PMC: 10921528. DOI: 10.1136/bmjopen-2023-078320.


Prognostic potential of nutritional risk screening and assessment tools in predicting survival of patients with pancreatic neoplasms: a systematic review.

Yu M, Li X, Chen M, Liu L, Yao T, Li J Nutr J. 2024; 23(1):17.

PMID: 38310276 PMC: 10837871. DOI: 10.1186/s12937-024-00920-w.


References
1.
Gul B, Metintas S, Ak G, Yilmaz S, Metintas M . The relationship between nutritional status and prognosis in patients with locally advanced and advanced stage lung cancer. Support Care Cancer. 2020; 29(6):3357-3365. DOI: 10.1007/s00520-020-05856-5. View

2.
Shoji F, Haratake N, Akamine T, Takamori S, Katsura M, Takada K . The Preoperative Controlling Nutritional Status Score Predicts Survival After Curative Surgery in Patients with Pathological Stage I Non-small Cell Lung Cancer. Anticancer Res. 2017; 37(2):741-747. DOI: 10.21873/anticanres.11372. View

3.
Hu B, Yang X, Xu Y, Sun Y, Sun C, Guo W . Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014; 20(23):6212-22. DOI: 10.1158/1078-0432.CCR-14-0442. View

4.
Cortot A, Audigier-Valette C, Molinier O, Moulec S, Barlesi F, Zalcman G . Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study. Eur J Cancer. 2020; 131:27-36. DOI: 10.1016/j.ejca.2020.02.022. View

5.
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin D, Pineros M . Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2018; 144(8):1941-1953. DOI: 10.1002/ijc.31937. View